To describe the treatment of 11 patients with radiobiologically guided dose-painting radiotherapy and report on toxicity.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Boost volumes were identified with functional magnetic resonance imaging scans in 11 patients with high-risk prostate cancer.
Patients were treated using a dose-painting approach; the boost dose was limited to 86 Gy in 37 fractions, while keeping the rectal normal tissue complication probability to 5-6%. Rotational intensity-modulated radiotherapy was used with daily image guidance and fiducial markers.
The median dose to the prostate (outside the boost volume) and urethra was 75. 4 Gy/37 fractions (range 75. 1-75. 8 Gy), whereas the median boost dose was 83. 4 Gy (range 79. 0-87. 4 Gy). The tumour control probability (TCP) (Marsden model) increased from 71% for the standard plans to 83. 6% [76. 6-86. 8%] for the dose-painting boost plans. The mean (Lyman-Kutcher-Burman) normal tissue complication probability for rectal bleeding was 5. 2% (range 3. 3-6. 2%) and 5. 2% for faecal incontinence (range 3. 6-7. 8%). All patients tolerated the treatment well, with a low acute toxicity profile. At a median follow-up of 36 months (range 24-50) there was no grade 3 late toxicity. Two patients had grade 2 late urinary toxicity (urethral stricture, urinary frequency and urgency), one patient had grade 1 and one grade 2 late rectal toxicity. The mean prostate-specific antigen at follow-up was 0. 81 ng/ml after stopping hormone therapy; one patient relapsed biochemically at 32 months (2. 70 ng/ml).
The toxicity for this radiobiological guided dose-painting protocol was low, but we have only treated a small cohort with limited follow-up time. The advantages of this treatment approach should be established in a clinical trial.
Clinical oncology (Royal College of Radiologists (Great Britain)). 2015 Oct 15 [Epub ahead of print]
J Uzan, A E Nahum, I Syndikus
Physics Department, Clatterbridge Cancer Centre, Bebington, UK. , Physics Department, Clatterbridge Cancer Centre, Bebington, UK. , Radiotherapy Department, Clatterbridge Cancer Centre, Bebington, UK.